- Home
- CERS vs LUNG Comparison
CERS vs LUNG Comparison
Compare CERS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERS
- LUNG
- Stock Information
- Founded
- CERS 1991
- LUNG 1995
- Country
- CERS United States
- LUNG United States
- Employees
- CERS N/A
- LUNG N/A
- Industry
- CERS EDP Services
- LUNG Industrial Specialties
- Sector
- CERS Technology
- LUNG Health Care
- Exchange
- CERS Nasdaq
- LUNG Nasdaq
- Market Cap
- CERS 347.3M
- LUNG N/A
- IPO Year
- CERS 1997
- LUNG 2020
- Fundamental
- Price
- CERS $1.40
- LUNG $6.73
- Analyst Decision
- CERS Strong Buy
- LUNG Strong Buy
- Analyst Count
- CERS 2
- LUNG 7
- Target Price
- CERS $3.50
- LUNG $12.64
- AVG Volume (30 Days)
- CERS 1.5M
- LUNG 241.2K
- Earning Date
- CERS 05-01-2025
- LUNG 04-30-2025
- Dividend Yield
- CERS N/A
- LUNG N/A
- EPS Growth
- CERS N/A
- LUNG N/A
- EPS
- CERS N/A
- LUNG N/A
- Revenue
- CERS $180,270,000.00
- LUNG $83,789,000.00
- Revenue This Year
- CERS $25.22
- LUNG $17.96
- Revenue Next Year
- CERS $10.08
- LUNG $18.35
- P/E Ratio
- CERS N/A
- LUNG N/A
- Revenue Growth
- CERS 15.29
- LUNG 22.01
- 52 Week Low
- CERS $1.35
- LUNG $5.46
- 52 Week High
- CERS $2.54
- LUNG $10.01
- Technical
- Relative Strength Index (RSI)
- CERS 37.22
- LUNG 39.84
- Support Level
- CERS $1.40
- LUNG $7.65
- Resistance Level
- CERS $1.58
- LUNG $7.02
- Average True Range (ATR)
- CERS 0.08
- LUNG 0.46
- MACD
- CERS 0.00
- LUNG -0.14
- Stochastic Oscillator
- CERS 20.83
- LUNG 19.19
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.